An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Thank you

Trial Information

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia


Inclusion Criteria:



- Successful completion of the CSTI571A 0110 E1 study

- Written informed consent for the extension CSTI571A0110E2

Exclusion Criteria:

- none

Other protocol-defined inclusion/exclusion criteria may apply.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To enable patients to continue to have access to study treatment

Outcome Time Frame:

December 31, 2011

Safety Issue:

No

Principal Investigator

Novartis Pharmaceuticals

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals

Authority:

United States: Food and Drug Administration

Study ID:

CSTI571A0110E2

NCT ID:

NCT00171223

Start Date:

August 2004

Completion Date:

April 2013

Related Keywords:

  • Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
  • Chronic Myelogenous Leukemia
  • CML
  • Philadelphia Chromosome
  • Accelerated phase
  • Acute Myelogenous Leukemia
  • AML
  • Acute Lymphoblastic Leukemia
  • ALL
  • Imatinib mesylate
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Name

Location
University of Michigan Ann Arbor, Michigan  48109-0624
Johns Hopkins Oncology Center Baltimore, Maryland  21287
UCLA Medical Center Los Angeles, California  90095-7059
Oregon Health & Sciences University Portland, Oregon  97201
New York Presbyterian Hospital New York, New York  10021
Wayne State University/Kamanos Cancer Center Detroit, Michigan  48201
H. Lee Moffet Cancer Center & Research Institute/Univ of South Florida Tampa, Florida  33612
Northwestern Univ meical School/Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois  60611
Dana Faber Cancer Institute Boston, Massachusetts  02115
C/O V. Ward - Washington Univ. school of Medicine St. Louis, Missouri  63110
MD Anderson Cancer Center, University of Texas Houston, Texas  77030